Research & Development


InterveXion’s anti-METH therapies work by preventing the abused drug from rapidly reaching the brain in large quantities. These therapies involve antibodies that can “absorb” METH in the blood to block their rewarding effects and simultaneously reduces their detrimental health effects. In addition to reducing the acute effects of overdose, these antibodies may also be used in the chronic setting to help abusers overcome their dependency.